The best treatment options for binge-eating disorder are unclear.
B
inge-eating disorder (BED), the most common eating disorder, affects approximately 3% of U.S. adults in their lifetime (1) (2) (3) . It is characterized by recurrent (≥1 per week for 3 months), brief (≤2 hours), psychologically distressing binge-eating episodes during which patients sense a lack of control and consume larger amounts of food than most people would under similar circumstances. Full diagnostic criteria are available in Appendix Table 1 (available at www.annals.org). Binge-eating disorder is more common in women (3.5%) than men (2.0%) and in obese individuals (5% to 30%) (4, 5) , especially those who are severely obese and those seeking obesity treatment (3, 6) . It typically emerges in early adulthood (1, 7) but may surface in adolescence (8) and persist well beyond midlife (9). In May 2013, the American Psychiatric Association (APA) officially recognized BED as a distinct eating disorder with a lower diagnostic threshold (in terms of frequency and duration of symptoms) than formerly accepted (10). The numbers of persons presenting for evaluation, receiving a BED diagnosis, and requiring treatment are expected to increase (11, 12) .
BED is associated with poorer psychological and physical well-being, including major depressive and other psychiatric disorders (13, 14), relationship distress and impaired social role functioning (14 -16), chronic pain (13, 14), obesity (13, 14, 17), and diabetes (18 -21). Binge eating and BED predispose individuals to metabolic syndrome independent of weight gain (17), type 2 diabetes (22), earlier-onset diabetes (20), and worse diabetes-related complications and outcomes owing to nonadherence to recommended dietary modifications (23) (24) (25) . Similarly, binge eating is implicated as a treatment-limiting factor in patients undergoing bariatric surgery, approximately 25% of whom experience "loss-of-control" eating (26) that interferes with adherence to postsurgical nutritional recommendations and may impede weight loss and reduce quality of life (27, 28) .
Treatment aims to reduce binge-eating frequency and disordered eating-related cognitions, improve metabolic health and weight (in patients who are obese, diabetic, or both), and regulate mood (in patients with coexisting depression or anxiety). Treatment approaches include psychological and behavioral treat-ments (hereafter "psychological"), pharmacologic treatments, and combinations of the 2 approaches. Table 1 describes common treatments for BED.
Current guidelines from the APA (29, 30) and the National Institute for Health and Care Excellence (NICE) (31) support the use of cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors, but they differ in content and timing. The APA recommends a team approach (including psychiatrists, psychologists, dietitians, and social workers) with CBT as the cornerstone and medication as adjunctive therapy. In contrast, NICE recommends a CBT-based self-help approach but also endorses medication monotherapy as sufficient treatment for some patients. Best practices for weight management are unclear, in part because of different perspectives on dieting-based approaches (32, 33) and bariatric surgery (34 -37) in obese individuals with BED. Moreover, little is known about the effect of patient-, provider-, and setting-level factors on treatment outcomes.
Our group at the RTI International-University of North Carolina Evidence-Based Practice Center conducted a systematic review for the Agency for Healthcare Research and Quality (AHRQ) (38) that updates and extends the scope of our 2006 AHRQ review on eating disorders (39, 40) by including studies of loss-ofcontrol eating, examining nearly twice as many randomized, controlled trials (RCTs) of BED therapies, and applying meta-analytic techniques to measure BED treatment effectiveness.
METHODS
Our methods, complete search strategies, and detailed evidence tables are available in the full systematic review (38) . Our protocol (41) was guided by key questions reflecting previously identified evidence gaps, input from key informants and a technical expert panel, and analytic frameworks depicting treatment effectiveness and harms (Appendix Figure 1 , available at www.annals.org). Key questions focused on the effectiveness of psychological treatments compared with waitlist, pharmacologic treatments compared with placebo, and combination treatments compared with placebo or waitlist. Primary outcomes were behavioral (reducing binge-eating frequency and increasing abstinence from binge eating), psychological (improving levels of eating-related and general psychological outcomes), and physical (reducing weight and improving other markers of health where relevant), and also included harms from treatment.
Data Sources and Searches
We searched EMBASE, the Cochrane Library, Academic OneFile, CINAHL, and ClinicalTrials.gov from inception to 18 November 2015, and MEDLINE from inception to 12 May 2016 (Supplement, available at www .annals.org). We hand-searched reference lists and relevant systematic reviews.
Study Selection
We used a PICOTS (populations, interventions, comparators, outcomes, timing, settings, and study designs) approach to identify studies that met our inclusion and exclusion criteria. Psychological, behavioral, or both CBT Focuses on identifying relationships among thoughts, feelings, and behaviors; aims to reduce negative emotions and undesirable behavior patterns by changing negative thoughts about oneself and the world. CBT may be delivered in various forms according to the level of therapist involvement-e.g., from therapist engaged in all aspects of treatment (therapist-led CBT) to no therapist engagement (self-help CBT). In self-help CBT, the patient follows a treatment manual or book, either with the help of a facilitator (e.g., guided or structured self-help) or alone. CBT may be tailored to the patient by focusing on problematic eating-related cognitions and behaviors. Dialectical behavior therapy Focuses on increasing mindfulness and developing skills to improve emotion regulation, distress tolerance, and interpersonal relationships to help patients respond to stress and negative affect more effectively.
Interpersonal psychotherapy
Focuses on identifying and changing the role of interpersonal functioning in causing and maintaining negative mood, psychological distress, and unhealthy behaviors. Behavioral weight loss
Incorporates various behavioral strategies to promote weight loss, such as restricting caloric intake and increasing physical activity.
limited inclusion to RCTs that measured outcomes at the end of treatment or later in 10 or more randomly assigned patients; included active intervention, placebo, or waitlist control groups as comparators; were conducted in outpatient, inpatient, or home-based settings (such as self-help); and were published in English. We included trials conducted in any country. We selected abstracts for full-text review of articles if they met predefined inclusion and exclusion criteria (Appendix Table 2 , available at www.annals.org). Two reviewers independently evaluated the full texts of selected articles to determine whether they should be included; disagreements were resolved by consensus discussion or with help from a third senior reviewer.
Data Abstraction and Risk-of-Bias Assessment
One reviewer abstracted details regarding study design, patient population, interventions and comparators, outcomes, duration of treatment and follow-up, settings, and results. A second reviewer checked the abstracted data for accuracy. For each study, 2 independent reviewers rated the risks of selection, performance, attrition, detection, and outcome reporting bias; they summarized their assessment overall as low, medium, or high risk of bias.
Statistical Analysis
For our investigation of treatments, we omitted studies with high risk of bias, except for harms and sensitivity analyses of meta-analyses. We graded the strength of evidence (SOE) for each major outcome with guidance from the Evidence-Based Practice Center regarding study limitations, consistency, precision, directness of the evidence, and risk of reporting bias (42, 43) . The SOE grades are high, moderate, low, or insufficient, reflecting levels of confidence that the evidence represents the true effect. A grade of insufficient means that evidence either was unavailable or did not permit estimation of the effect. In this review, we report results with SOE grades of low, moderate, or high; see the technical report for more detailed results, including those with insufficient SOE (38) .
For available trials using comparable treatment methods, durations, and outcomes, we performed an unadjusted random-effects meta-analysis using restricted maximum likelihood models (OpenMeta[Analyst] [Brown University Center for Evidence-Based Medicine]). Across studies, the percentage of patients achieving abstinence for each trial uses the number of all randomly assigned patients as the denominator to reflect a true intention-to-treat analysis (that is, to correct variations in results of modified intention-to-treat analyses from individual trials). We derived risk ratios (RRs) for abstinence (defined as 0 binge episodes recorded in the most recent assessment period, usually the past month) and mean differences (MDs) for binge episodes per week, binge days per week, eatingrelated obsessions and compulsions, body mass index (BMI), weight, and depression scores. We assessed statistical heterogeneity using the I 2 statistic. In considering psychological studies for pooled analyses, we did not combine data from studies using different modes of delivery (for example, individual and group therapy) for the same treatment. If relevant, we conducted sensitivity analyses to measure the effect on pooled results of including studies rated high risk of bias. We also conducted qualitative syntheses of trials with interventions or outcomes that we judged insufficiently similar for meta-analysis.
Role of the Funding Source
This research was funded by AHRQ. Agency staff participated in developing the scope of the work, refining the analytic framework and key questions, resolving issues regarding the project scope, reviewing the draft report, and distributing it for peer review. AHRQ did not engage in selecting studies, assessing risk of bias, or synthesizing or interpreting data. The authors are solely responsible for the content and the decision to submit this manuscript for publication.
RESULTS

Overview of Trials
We identified 34 trials with low or medium risk of bias (Appendix Figure 2 and Appendix Table 3 , available at www.annals.org). Of these, 9 were waitlistcontrolled psychological trials and 25 were placebocontrolled trials in which the active comparator was medication only (n = 19) or a combination treatment (n = 6). The psychological trials examined various forms of BED-focused CBT including self-help, psychodynamic interpersonal psychotherapy, dialectical behavior therapy, and behavioral weight loss treatment. The medication-only trials included anticonvulsants (topiramate and lamotrigine), antiobesity agents (orlistat), central nervous system stimulants (lisdexamfetamine), a dietary supplement (chromium picolinate), various second-generation antidepressants (SGAs; for example, citalopram, fluoxetine, and sertraline), and other medications (including acamprosate and armodafinil). Each of the 6 combination trials used a different behavioral plus medication approach.
Most trials (26 of 34) were conducted in the United States; the mean age ranged from 36 to 47 years, and most participants were female (≥77%), white, and overweight or obese (mean BMI, 28.8 to 41.1 kg/m 2 ). Trial sizes ranged from 24 to 394 randomly assigned participants, and treatment lasted 6 weeks to 6 months. Posttreatment follow-up assessments of the randomly assigned sample occurred in only 5 trials. Most studies excluded individuals receiving psychotropic medications; participants generally reported low to moderate levels of depression symptoms at baseline.
Sixteen trials contributed to the meta-analyses of key outcomes: 5 evaluated therapist-led CBT (44 -48), 3 studied lisdexamfetamine (49 -52) , and 8 examined SGAs (fluoxetine, 60 mg/d [53] or 80 mg/d [54] ; bupropion [55]; citalopram [56] ; duloxetine [57] ; escitalopram [58] ; fluvoxamine [59] ; and sertraline [60] ). In these trials, 342 participants were randomly assigned to therapist-led CBT or a waitlist, 416 to an antidepressant or placebo, and 983 to lisdexamfetamine or pla-cebo. Of 583 patients randomly assigned to the lisdexamfetamine groups, our analysis included 517 who received at least 50 mg/d, because this is the minimum dosage approved by the U.S. Food and Drug Administration for BED treatment. We qualitatively synthesized data for additional outcomes from these as well as the remaining 18 trials.
Outcomes
For each outcome, we first present the metaanalytic results in the text and supporting figures, then present the results of trials not included in the metaanalysis. Table 2 summarizes the qualitative findings for each trial, including the SOE grade for differences (or no differences) between interventions and comparators, which was low or moderate for all findings except one: weight reduction with lisdexamfetamine. Outcomes with insufficient SOE are not mentioned but may be found in the main report (38) .
Binge-Eating Outcomes
More participants achieved abstinence from binge eating with therapist-led CBT versus waitlist (58 On the basis of qualitative syntheses, partially therapist-led CBT, guided self-help CBT, and topiramate increased bingeeating abstinence and reduced binge-eating frequency, and therapist-led CBT and structured self-help CBT reduced binge-eating frequency ( Table 2) . On the basis of qualitative analyses, topiramate decreased eating-related obsessions and compulsions and therapist-led CBT and guided self-help CBT consistently improved eating-related psychopathology, as reflected in participants' susceptibility to hunger; cognitive control over eating; and overall concerns about eating, shape, and weight ( Table 2) .
Eating-Related Psychological Outcomes
Symptoms of Depression and Other Psychological and Psychosocial Outcomes
SGAs significantly reduced scores on the Hamilton Rating Scale for Depression (HAM-D) ( On the basis of qualitative syntheses, reductions in BMI did not differ significantly between patients on waitlist and those receiving therapist-led, partially therapistled, or structured self-help CBT ( Table 2 ). In contrast, compared with placebo, lisdexamfetamine and topiramate resulted in greater weight reductions ( Table 2) . Several trials reported on weight-related metabolic variables; however, evidence was sufficient only for lisdexamfetamine reducing triglyceride levels compared with placebo ( Table 2) .
Harms Associated With Treatment
No psychological treatment studies reported harms. Of the 25 placebo-controlled medication-only or medication-plus-psychological intervention trials reviewed here, 20 reported on harms. Most involved medication side effects widely documented in non-BED populations. Four serious adverse events occurred in the 3 lisdexamfetamine trials.
In ) . Qualitatively, the incidence of decreased appetite with lisdexamfetamine, SNS arousal with topiramate and fluvoxamine, and gastrointestinal upset and sleep disturbance with fluvoxamine was greater than that observed with placebo (Appendix Table 4 , available at www.annals.org).
Treatment was discontinued infrequently, but approximately twice as often among patients assigned to medication alone or to a combined intervention (n = 98; 13 of whom had a serious adverse event) than in the placebo group (n = 43; 7 of whom had a serious adverse event). Participants dropped out of psychological trials most often because of dissatisfaction.
DISCUSSION
This review contributes new knowledge from an expanded treatment evidence base that permitted estimates of treatment effect sizes and harms from pooled analyses of therapist-led CBT, lisdexamfetamine, and SGAs not provided in our 2006 AHRQ report (39) with medication) but excluded trials of sibutramine (which no longer is available in the United States), as well as studies of zonisamide, atomoxetine, and fluvoxamine that we rated as high risk of bias. Our findings provide strong support for therapist-led CBT, lisdexamfetamine, and SGAs (as a group) in helping patients with BED reduce binge-eating frequency and achieve abstinence; with less confidence, they suggest similar benefits from topiramate and other forms of CBT. Effect estimates varied in magnitude and cannot be compared easily across treatments because we could not do pooled analyses on any single SGA and because the comparators for CBT and lisdexamfetamine differed (waitlist and placebo, respectively). Patients seeking treatment for BED have various degrees of distress associated with binge eating-related obsessive thoughts and compulsions, worries about their shape and weight, and negative mood symptoms. With varying levels of certainty, our findings indicate that CBT in several formats, lisdexamfetamine, SGAs, and topiramate reduce these problems. The evidence from nearly 1000 patients was especially strong for lisdexamfetamine in reducing obsessions, compulsions, and weight. In overweight and obese individuals without BED, topiramate tends to induce weight loss (83) , whereas SGAs tend to be weight-neutral (84), al- Despite the high levels of co-occurrence of BED with depression and other psychiatric conditions (85), we found no clear benefit of various forms of CBT in reducing symptoms of depression; limited evidence indicated a slight benefit with SGAs. This result may reflect 2 factors: Included trials generally comprised participants with low levels of negative mood symptoms at baseline (and not necessarily a clinical diagnosis of depression), and CBT was tailored to address problematic eating-related cognitions and behaviors unique to BED rather than global depressive cognitions and behaviors.
Although the number of serious treatment harms was extremely low, harms of any type, discontinuation of treatment attributed to harms, and the number of serious adverse events were approximately 2-fold greater among those receiving an active medication than among those receiving a placebo. Based on metaanalytic and qualitative results, harms occurred more frequently in patients treated with lisdexamfetamine, topiramate, or fluvoxamine than in those receiving a placebo. The most commonly reported harm in all trials, SNS arousal, occurred more than 4 times as frequently with lisdexamfetamine than placebo.
Clinicians should be aware of the potential for lisdexamfetamine to decrease appetite. Depending on a patient's treatment goals and propensity toward food restriction, this side effect may be helpful or harmful Favors treatment RR = risk ratio.
and should be monitored closely. Cycling between dietary restraint and binge eating is common among individuals with BED (86 -88); many restrict food intake during the day and binge eat in the evening. In addition, many individuals with BED experience deficits in appetite awareness (89, 90) . Theoretically, the potential for harm may be greater among these groups. In January 2015, lisdexamfetamine became the first (and only) drug approved by the U.S. Food and Drug Administration for treating patients with BED. A central nervous system stimulant and dextroamphetamine prodrug, lisdexamfetamine is recognized widely as an effective treatment for reducing symptoms of impulsivity, inattention, and hyperactivity in children and adults with attention deficit-hyperactivity disorder, in whom it is well-tolerated with generally manageable side effects, such as dry mouth, restlessness, insomnia, and gastrointestinal upset (91) . Our meta-analyses show tolerability and efficacy of lisdexamfetamine in BED, including clinically meaningful short-term reductions in binge-eating frequency and in obsessive thoughts and compulsions regarding binge eating. Because the U.S. Drug Enforcement Administration classifies lisdexamfetamine as a Schedule II drug, individuals with a history of stimulant or other substance use disorder, suicide attempt, mania, or cardiac disease or abnormality were excluded from the trials; therefore, the results may not generalize to these BED populations.
In the United States, clinical practice guidelines tend to favor therapist-led CBT augmented with psychotropic medication (typically an antidepressant) as needed (29, 30) . Many patients, however, have only limited access to BED-focused CBT with a BED-trained psychotherapist within a multidisciplinary team including a psychiatrist. The self-help approach recommended by NICE may be advantageous for overcoming this barrier to treatment access and increasing treatment dissemination. However, given the low SOE derived from our qualitative findings, recommending self-help CBT as first-line treatment would be premature. Our report cannot resolve the apparent discrepancy between the APA and NICE recommendations regarding when and how to integrate psychological, behavioral, and pharmacologic treatments for BED. Adequately powered head-to-head comparative effectiveness trials are needed to determine equivalence or noninferiority of self-help compared with therapistled CBT.
Several limitations of the evidence base and review exist. The efficacy evidence base comprised only small samples or methodologically disparate single studies for nearly all medications, many psychological treatments, and all combination treatments. As a result, the evidence was insufficient to generate pooled estimates for self-help CBT or to evaluate the efficacy of specific antidepressants, promising interventions (such as interpersonal psychotherapy) (92, 93) , complementary and alternative medicine or nutraceutical approaches, combination treatments (74, 82) , or stepped-care strategies. Some trials had methodological limitations, including unclear randomization and allocation concealment, unmasked outcome assessors, and differential attrition between treatment groups. The instruments used to assess psychological outcomes, as well as how investigators reported outcomes, varied considerably. Moderate to high heterogeneity characterized the pooled estimates of some outcomes for some treatments, in several cases leading us to downgrade the SOE to moderate (for example, the effect of lisdexamfetamine on psychopathology and SNS arousal) or low (for example, the effect of SGAs on psychopathology). Studies did not report adverse events and discontinuations uniformly. Other limitations included trial setting (mainly supervised outpatient settings in U.S. academic research and medical centers) and population (mostly overweight or obese, 20-to 40-year-old white women with low levels of depression and anxiety), preventing us from assessing the effect of important patient characteristics, such as race, body weight, or presence of psychological or medical comorbidity, on treatment efficacy. Although publication bias and selective reporting were possible, many statistically nonsignificant results were reported in the trials, and a review of a sample of non-English abstracts (n = 358) and articles (n = 9) did not suggest a language bias or that any important psychological and medication trials were missing. Lastly, as no pharmacologic studies had longterm follow-up, persistence of efficacy benefits beyond active treatment could not be evaluated.
Among adults with BED, strong evidence indicates that therapist-led CBT, lisdexamfetamine, and SGAs as a general class (mainly selective serotonin reuptake inhibitors) reduce the frequency of binge eating, increase the likelihood of achieving abstinence from binge eating, and improve other eating-related psychological outcomes. Similar but less compelling evidence shows a benefit from other forms of CBT and topiramate. Harms associated with lisdexamfetamine, SGAs, and topiramate rarely limited treatment. It is unclear whether these findings generalize to patients with BED beyond those included in these trials (chiefly, overweight or obese 20-to 40-year-old white women without psychological or medical comorbidity). Adequately powered trials are needed to evaluate the comparative long-term benefits of psychological and pharmacologic treatments. Given the high levels of association among BED, obesity, and depression, future studies should determine whether certain treatments are better suited for particular subsets of patients. 
